


Claims

1. A compound of formula (I)



wherein

- | | |
|-----------------------------------|--|
| R ¹ | is halogen, lower C ₁₋₇ -alkyl, C₁₋₇ lower -haloalkyl, lower C ₁₋₇ -hydroxyalkyl, lower C ₁₋₇ -alkoxy, lower C ₁₋₇ -alkoxy- lower C ₁₋₇ -alkyl, -C(O)-NR ⁹ R ¹⁰ , aryl, heteroaryl or NR ⁷ R ⁸ , wherein said aryl and said heteroaryl can be substituted by 1 to 3 substituents independently selected from the group consisting of hydroxyl, halogen, lower C ₁₋₇ -alkyl, lower C ₁₋₇ -alkoxy, lower C ₁₋₇ -alkoxy- lower C ₁₋₇ -alkyl, lower C ₁₋₇ -haloalkyl and lower C ₁₋₇ -haloalkoxy; |
| R ² | is hydrogen, halogen, C₁₋₇ lower -alkyl, C₁₋₇ lower -haloalkyl, C₁₋₇ lower -hydroxyalkyl, C₁₋₇ lower -alkoxy or C₁₋₇ lower -alkoxy- C₁₋₇ lower -alkyl; |
| R ³ | is hydrogen, C₁₋₇ lower -alkyl, C₁₋₇ lower -haloalkyl, C₁₋₇ lower -hydroxyalkyl, C₁₋₇ lower -alkoxy or C₁₋₇ lower -alkoxy- C₁₋₇ lower -alkyl; |
| R ⁴ | is hydroxyl, C₁₋₇ lower -alkoxy or NR ⁵ R ⁶ ; |
| R ⁵ and R ⁶ | are independently hydrogen, C₁₋₇ lower -alkyl, C₁₋₇ lower -haloalkyl, C₁₋₇ lower -hydroxyalkyl, C₁₋₇ lower -alkoxy- C₁₋₇ lower -alkyl, cycloalkyl or heterocyclyl, or R ⁵ and/or R ⁶ are C₁₋₇ lower -alkyl substituted by a substituent selected from the group consisting of heteroaryl, C₁₋₇ lower -alkyl-heteroaryl and C₁₋₇ lower -alkoxy-C(O)-, or |
- R⁵ and R⁶, together with the nitrogen atom to which they are attached, form a heterocyclyl, bicyclo-heterocyclyl or spiro-heterocyclyl, wherein said heterocyclyl can be substituted

by 1 to 3 substituents independently selected from the group consisting of hydroxyl, halogen, C₁₋₇-lower-alkyl, C₁₋₇-lower-alkoxy, C₁₋₇-lower-alkoxy-C₁₋₇-lower-alkyl, C₁₋₇-lower-haloalkyl and oxo;

R⁷ and R⁸ are independently hydrogen, C₁₋₇-lower-alkyl, C₁₋₇-lower-haloalkyl, C₁₋₇-lower-hydroxyalkyl, C₁₋₇-lower-alkoxy-C₁₋₇-lower-alkyl or cycloalkyl, or

R⁷ and R⁸, together with the nitrogen atom to which they are attached, form a heterocyclyl optionally substituted by a substituent selected from the group consisting of hydroxyl, halogen and oxo; and


R⁹ and R¹⁰ are independently hydrogen, C₁₋₇-lower-alkyl, C₁₋₇-lower-haloalkyl, C₁₋₇-lower-hydroxyalkyl or C₁₋₇-lower-alkoxy-lower-alkyl,

wherein heteroaryl refers to an aromatic 5- or 6-membered monocyclic ring or 9- or 10-membered bicyclic ring which comprises 1, 2 or 3 atoms independently selected from nitrogen, oxygen and/or sulphur,

wherein heterocyclyl refers to a monovalent saturated 4- to 6-membered monocyclic ring containing one, two or three ring heteroatoms independently selected from N, O and S,

or a pharmaceutically acceptable salt thereof.

2. A The compound of formula (I) claim 1,



wherein

R¹ is C₁₋₇-lower-alkyl, -C(O)-NH-C₁₋₇-lower-haloalkyl, aryl, heteroaryl or NR⁷R⁸, wherein said aryl and said heteroaryl can be substituted by 1 to 3 substituents independently selected from the group consisting of hydroxyl, halogen, C₁₋₇-lower-alkyl, C₁₋₇-lower-alkoxy and C₁₋₇-lower-haloalkyl;

R² is hydrogen, halogen or C₁₋₇-lower-alkyl;

R³ is hydrogen or C₁₋₇-lower-alkyl;

R⁴ is hydroxyl, ~~C₁₋₇lower-alkoxy~~ or NR⁵R⁶;

R⁵ and R⁶ are independently hydrogen, ~~C₁₋₇lower-alkyl~~, ~~C₁₋₇lower-haloalkyl~~, ~~C₁₋₇lower-alkoxy-~~
~~C₁₋₇lower-alkyl~~, ~~C₁₋₇lower-alkyl~~ substituted by ~~C₁₋₇lower-alkyl-heteroaryl~~ or heterocyclyl, or

R⁵ and R⁶, together with the nitrogen atom to which they are attached, form a heterocyclyl which can be substituted by 1 to 3 substituents independently selected from the group consisting of hydroxyl, halogen, ~~C₁₋₇lower-alkyl~~, ~~C₁₋₇lower-alkoxy~~, ~~C₁₋₇lower-haloalkyl~~ and oxo; and

R⁷ and R⁸ are independently ~~C₁₋₇lower-alkyl~~ or, together with the nitrogen atom to which they are attached, form a morpholinyl ring,

or a pharmaceutically acceptable salt thereof.

3. The compound or a pharmaceutically acceptable salt thereof according to ~~any one of~~
~~claims 1 to 2~~claim 1, wherein R¹ is halogen, ~~C₁₋₇lower-alkyl~~, -C(O)-NR⁹R¹⁰, phenyl, pyridinyl or NR⁷R⁸, wherein said phenyl and said pyridinyl can be substituted by 1 to 3 substituents independently selected from the group consisting of hydroxyl, halogen, ~~C₁₋₇lower-alkyl~~, ~~C₁₋₇lower-alkoxy~~, ~~C₁₋₇lower-haloalkyl~~ and ~~C₁₋₇lower-haloalkoxy~~; R⁷ and R⁸ are independently ~~C₁₋₇lower-alkyl~~, ~~C₁₋₇lower-haloalkyl~~ or cycloalkyl, or R⁷ and R⁸, together with the nitrogen atom to which they are attached, form pyrrolidin-1-yl, 2-oxopyrrolidin-1-yl or morpholin-4-yl; and R⁹ and R¹⁰ are independently hydrogen, ~~C₁₋₇lower-alkyl~~, ~~C₁₋₇lower-haloalkyl~~ or ~~C₁₋₇lower-alkoxy-~~ ~~C₁₋₇lower-alkyl~~.

4. The compound or a pharmaceutically acceptable salt thereof according to ~~any one of~~
~~claims 1 to 3~~claim 3, wherein R¹ is phenyl, 3-fluorophenyl, 2-methoxyphenyl, 3-methoxy-phenyl, pyridin-3-yl, 2-fluoropyridin-4-yl, dimethylamino, ethyl-methyl-amino cyclopropyl-methyl-amino, pyrrolidin-1-yl or morpholin-4-yl.

5. The compound or a pharmaceutically acceptable salt thereof according to any one of
claims 1 to 4, wherein R² is hydrogen, halogen or ~~C₁₋₇lower-alkyl~~.

6. The compound or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 5, wherein R² is hydrogen.

7. The compound or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 6, wherein R³ is methyl.

8. The compound or a pharmaceutically acceptable salt thereof according to any one of claims 1, 3 to 7,

wherein

R⁴ is hydroxyl, C₁₋₇~~lower~~-alkoxy or NR⁵R⁶;

R⁵ and R⁶ are independently hydrogen, C₁₋₇~~lower~~-alkyl, C₁₋₇~~lower~~-haloalkyl, C₁₋₇~~lower~~-hydroxyalkyl, C₁₋₇~~lower~~-alkoxy-C₁₋₇~~lower~~-alkyl, cyclopropyl, cyclopentyl, oxetanyl or tetrahydrofuranyl, or R⁵ and/or R⁶ are C₁₋₇~~lower~~-alkyl substituted by a substituent selected from the group consisting of C₁₋₇~~lower~~-alkyl-pyridinyl and methoxycarbonyl, or

R⁵ and R⁶, together with the nitrogen atom to which they are attached, form a heterocyclyl selected from the group consisting of azetidiny, pyrrolidinyl, piperazinyl, morpholinyl and thiomorpholinyl, wherein said heterocyclyl can be substituted by 1 to 3 substituents independently selected from the group consisting of halogen, C₁₋₇~~lower~~-alkyl, C₁₋₇~~lower~~-alkoxy and oxo, or R⁵ and R⁶, together with the nitrogen atom to which they are attached, form 2-oxa-5-azabicyclo[2.2.1]heptanyl, 2-oxa-6-azaspiro[3.3]heptanyl or 1,4-diaza-bicyclo[3.2.1]octanyl.

9. The compound or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 8, wherein

R⁴ is NR⁵R⁶;

R⁵ and R⁶ are independently methyl, ethyl, 2-fluoroethyl, 2-methoxyethyl or cyclopropyl, or

13. The compound according to any one of claims 1 to 11 for use as therapeutically active substance.

14. A pharmaceutical composition comprising a compound in accordance with any one of claims 1 to 11 and a therapeutically inert carrier.

15. ~~The use of a compound according to any one of claims 1 to 11 for the preparation of a medicament for use in~~ the treatment or prophylaxis of psychotic disorders, schizophrenia, positive, negative and/or cognitive symptoms associated with schizophrenia, delusional disorder, substance-induced psychotic disorder, anxiety disorders, panic disorder, obsessive/compulsive disorders, acute stress disorder, generalized anxiety disorder, drug addictions, movement disorders, Parkinson's disease, restless leg syndrome, cognition deficiency disorders, Alzheimer's disease, multi-infarct dementia, mood disorders, depression, bipolar disorders, neuropsychiatric conditions, psychosis, attention-deficit/hyperactivity disorder, attentional disorders, diabetes and related disorders, type 2 diabetes mellitus, neurodegenerative disorders, Huntington's disease, multiple sclerosis, stroke, spinal cord injury, solid tumors, hematological malignancies, renal cell carcinoma or breast cancer.

16. ~~The compound according to any one of claims 1 to 11 for the treatment or prophylaxis of psychotic disorders, schizophrenia, positive, negative and/or cognitive symptoms associated with schizophrenia, delusional disorder, substance-induced psychotic disorder,~~

~~anxiety disorders, panic disorder, obsessive/compulsive disorders, acute stress disorder, generalized anxiety disorder, drug addictions, movement disorders, Parkinson's disease, restless leg syndrome, cognition deficiency disorders, Alzheimer's disease, multi-infarct dementia, mood disorders, depression, bipolar disorders, neuropsychiatric conditions, psychosis, attention deficit/hyperactivity disorder, attentional disorders, diabetes and related disorders, type 2 diabetes mellitus, neurodegenerative disorders, Huntington's disease, multiple sclerosis, stroke, spinal cord injury, solid tumors, hematological malignancies, renal cell carcinoma or breast cancer.~~

~~17. The compound according to any one of claims 1 to 11, when manufactured according to a process of claim 12.~~